Do GC and CYP2R1 variants lower circulating vitamin D?

Circulating vitamin D status is highly regulated by genetically determined transport and enzymatic activation pathways.

Molecular mechanisms of transport and activation

• GC-mediated transport: The GC gene encodes vitamin D-binding protein (DBP), which binds 85% to 90% of circulating 25-hydroxyvitamin D [25(OH)D]. The rs2282679 variant alters DBP concentrations and binding characteristics, modulating metabolite stability, transport, and renal clearance.
• CYP2R1-mediated activation: CYP2R1 is the principal hepatic 25-hydroxylase converting vitamin D to its primary circulating form, 25(OH)D. The rs10741657 variant reduces enzyme expression and activity, directly impairing this conversion step.

Clinical and genetic evidence

• GC rs2282679: Each risk allele for this variant is associated with a 3 to 4 ng/mL decrease in serum 25(OH)D and a 1.3- to 1.8-fold increase in the odds of vitamin D deficiency.
• CYP2R1 rs10741657: The G risk allele significantly lowers circulating 25(OH)D levels, increasing deficiency odds by 1.06- to 1.42-fold across large cohorts.
• Combined gene-dose effects: When inherited together, these variants exhibit an additive effect. Individuals carrying risk alleles at both loci experience lower baseline 25(OH)D levels, steeper seasonal declines, and a blunted response to vitamin D supplementation.

Bottom line

• Genetic variations in GC (rs2282679) and CYP2R1 (rs10741657) directly impair vitamin D transport and hepatic activation, robustly predicting lower circulating 25(OH)D levels and reduced responsiveness to supplementation.